SOURCE: MitoPharm Corporation

September 18, 2007 09:05 ET

MitoPharm Schedules Special Shareholder Conference Call to Discuss Successful Business Activities and Upcoming Corporate Initiatives

SEATTLE, WA--(Marketwire - September 18, 2007) - MitoPharm Corporation, Inc. (PINKSHEETS: MTPM), a biotechnology company, announced today that it will be hosting a special conference call to update MitoPharm shareholders on the company's recent business efforts, strengthened partner relationships and new management initiatives.

Peter Cheung, CEO of MitoPharm, commented, "We would typically schedule conference calls after the close of the fiscal year in order to detail various business activities that took place within the past year. However, we've recently had some very positive developments that will directly impact our company's finances and significantly improve our business plan. We anticipate these developments will also add considerable strength to our ability to be successful in bringing our products to market. With that in mind, we felt it was important to update our shareholders and interested investors at the earliest possible date."

The conference call will take place on October 5, 2007, and is expected to last approximately 30 minutes. The call will include a presentation by MitoPharm's senior management and a question and answer period. In order to ensure that shareholder questions can be fully answered, please submit all questions prior to the call so they may be grouped into general categories and addressed, as time permits. To submit a question, please email questions to or fax them to 888-573-5024, Attention: MitoPharm Conference Call. Details on the specific time of the conference call and special access phone/pin numbers will be available in the Investor Relations area of the MitoPharm website later in the week.

For further information, shareholders and non-shareholders are encouraged to contact the Company's Investor Relations:

     MitoPharm Corporation Investor Relations

About MitoPharm

MitoPharm, Inc. is an active research & development biotechnology firm that will operate in marketing, and sale of drugs, dietary supplements, and functional beverages. The initial products are based on a newly formulated compound, (-) Schisandrin B, that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology. Published scientific studies have confirmed that (-) Schisandrin B enhances the mitochondrial glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, plus it also induces the expression of heat shock proteins, another group of important molecules for cell protection. These biochemical actions differentiate (-) Schisandrin B from other existing, known compounds, either synthetic or naturally occurring, in its ability to protect organs including the heart, the liver, and the brain.

For further MitoPharm information, please visit

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward-looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.